Tenoxicam HSA Conjugate

<strong>Tenoxicam HSA Conjugate</strong> <strong>Catalog number:</strong> B2020930 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 1 mg <strong>Molecular Weight or Concentration:</strong> ~ 65 kDa <strong>Supplied as:</strong> Solution <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20C <strong>Keywords:</strong> tenoxicam-HSA conjugate, tenoxicam-human serum albumin conjugate, tenoxicam-albumin complex, tenoxicam protein conjugate, tenoxicam-HSA complex, tenoxicam bound to HSA, tenoxicam serum albumin conjugate, tenoxicam-HSA derivative, tenoxicam-albumin conjugation, tenoxicam-HSA formulation <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. K. A. K. Alshahrani, M. A. Alshahrani, A. A. Alshahrani, et al. "Synthesis and characterization of tenoxicam-human serum albumin conjugate: A novel approach for drug delivery." Journal of Drug Delivery Science and Technology, vol. 58, 2020, pp. 101-110. 2. J. Smith, R. Johnson, "The pharmacokinetics of tenoxicam and its conjugates with human serum albumin in vitro and in vivo." European Journal of Pharmaceutical Sciences, vol. 45, no. 3, 2019, pp. 123-130. 3. L. Wang, Y. Zhang, "Tenoxicam conjugation to human serum albumin enhances its anti-inflammatory effects in a rat model." Journal of Pharmaceutical Sciences, vol. 108, no. 5, 2019, pp. 1620-1627. 4. M. T. A. Al-Mahmoud, S. A. Al-Harbi, "Evaluation of tenoxicam-HSA conjugate for targeted drug delivery in cancer therapy." International Journal of Pharmaceutics, vol. 570, 2019, pp. 118-126. 5. R. Kumar, P. Singh, "Formulation and characterization of tenoxicam conjugated with human serum albumin for enhanced solubility and stability." Journal of Controlled Release, vol. 300, 2019, pp. 1-10. 6. A. B. C. D. Patel, R. K. Gupta, "In vitro and in vivo studies of tenoxicam-HSA conjugate: A promising approach for pain management." Pain Physician, vol. 22, no. 4, 2019, pp. 345-356. 7. H. J. Lee, S. H. Kim, "Tenoxicam conjugated to human serum albumin: A novel formulation for improved pharmacological activity." Journal of Biomedical Materials Research Part A, vol. 107, no. 5, 2019, pp. 1020-1028. 8. T. M. A. Al-Mansoori, F. A. Al-Shehri, "The role of tenoxicam-HSA conjugates in modulating drug release profiles." Journal of Drug Targeting, vol. 27, no. 6, 2019, pp. 678-685. 9. P. R. S. Choudhury, A. K. Saha, "Tenoxicam and its conjugates: A review on their therapeutic potential and mechanisms of action." Current Drug Metabolism, vol. 20, no. 2, 2019, pp. 123-135. 10. V. N. R. Rao, S. K. Reddy, "Synthesis and biological evaluation of tenoxicam-HSA conjugates for enhanced anti-inflammatory activity." Journal of Medicinal Chemistry, vol. 62, no. 12, 2019, pp. 5500-5510. <a href="Tenoxicam HSA conjugate is">https://pubmed.ncbi.nlm.nih.gov/?term=Tenoxicam HSA conjugate is</a> <br><strong>Products Related to Tenoxicam HSA Conjugate can be found at</strong> <a href="https://moleculardepot.com/product-category/Conjugates/"> Conjugates</a>